智通财经APP获悉，晶泰控股(02228)涨超6%，截至发稿，涨6%，报9.18港元，成交额17.82亿港元。
消息面上，8月20日，晶泰科技宣布与韩国领先的制药企业——韩国 Dong-A ST（东亚公司）签署合作备忘录（MOU），双方将基于晶泰科技的 AI+ 机器人研发平台，结合各自优势，共同开发针对免疫与炎症性疾病的创新疗法。本次合作将依托晶泰科技量子物理、人工智能（AI）、机器人实验驱动的智能药物研发平台，由两家公司共同确定靶点，从头设计和开发具有首创新药（first-in-class）或同类最优（best-in-class）潜力的候选药物。
此前，晶泰科技发布盈喜，预期上半年综合收益将不少于5亿元人民币，按年增加至少约387%；预期将转亏为盈录得纯利不少于5,000万元，为集团首次实现半年盈利。期内财务表现预期改善乃主要由于集团与DoveTree合作，集团基于端到端人工智能药物发现平台及综合“AI+机器人”技术，向DoveTree提供药物发现解决方案及服务，该合作带动重大收益增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.